Molecular profiling of the clinical response of liver cancer patients to combination therapy with anti-PD1 and lenvatinib(clinical data)
| Title | Molecular profiling of the clinical response of liver cancer patients to combination therapy with anti-PD1 and lenvatinib(clinical data) |
|---|---|
| Description | Combination therapy using tyrosine kinase inhibitor like Lenvatinib and anti-programmed death-1 receptor (PD1) immunotherapy represents an effective systemic treatment of unresectable hepatocellular carcinoma (uHCC). However, patients' responses vary considerably. The molecular responsiveness of HCC patients deserves to be explored and prediction method of potential responders remains to be investigated. |
| Organism | Homo sapiens |
| Data Type | Clinical Research data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA010833 |
| Release Date | 2024-08-06 |
| Submitter | Cheng Huang (huang.cheng@zs-hospital.sh.cn) |
| Organization | Zhongshan Hospital, Fudan University |
| Submission Date | 2022-08-06 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX001528-01 | clinical data | 79 | Clinical Research data | 8.6 MB | xlsx | 0 | Controlled |